- Product
- Losartan's re-prescription & re-dispensing are imminent
- by Jung, Heung-Jun Dec 6, 2021 05:54am
- While the government's follow-up measures based on the results of Losartan impurity detection are expected to be announced this week, attention is being paid to the work guidelines for re-prescription and re-prevention. Items with problems with all manufacturing numbers are expected to be re-prescribed and re-manufactured, and items with prob
- Policy
- KB Pharm's generic for Vildagliptin nitrate will be approved
- by Lee, Tak-Sun Dec 6, 2021 05:54am
- The post-inflammatory drugs of the diabetes treatment Galvusmet (Vildaglipin-Metformin Hydrochloride), which the Supreme Court ruled invalidating part of its extended duration, are appearing one after another. These items will be able to be released early in January next year if some of their duration is confirmed to be invalid. On the 30t
- Policy
- Asciminib's domestic approval is at a quick step
- by Lee, Tak-Sun Dec 6, 2021 05:53am
- Novartis' Asciminib, which is attracting attention as a fourth-generation targeted anticancer drug in the chronic leukemia treatment market, is also speeding up domestic permits. The drug, which was approved by the U.S. FDA last month, has recently been approved for four clinical plans in Korea alone, boosting the analysis that it is acce
- Product
- Why Tagrisso and Opdivo failed reimbursement expansions
- by Moon, sung-ho Dec 6, 2021 05:53am
- The 3rd generation targeted therapy for lung cancer, ‘Tagrisso (osimertinib)’ once again failed to expand reimbursement to first-line treatment. The reason was that the drug was more appropriate as a second-line treatment in terms of cost-effectiveness. By failing to expand reimbursement at the last Cancer Drug Review Committee meeting held
- Policy
- Companies in a dilemma over who bears losartan recall cost
- by Lee, Tak-Sun Dec 3, 2021 05:55am
- Pharmaceutical companies are unsatisfied with the health authorities’ request for companies to fully bear the cost of exchanging ‘losartan’ products that were found to contain azido impurities. While many companies have submitted the ‘cost-bearing letter of commitment,’ the companies have been left with a bitter aftertaste, due to
- Company
- Moderna Korea appoints Ji-Young Sohn as new GM
- by Dec 3, 2021 05:55am
- Ji-Young Sohn, the former GM of CSL Behring Korea, was appointed as the General Manager of the Korean subsidiary of the COVID-19 vaccine developer Moderna. The new GM will be leading Moderna’s business in Korea and is seeking executives to organize teams that can perform various tasks for the company. The company is currently hiring new
- Company
- COVID-19 vaccinations freeze up the premium vaccine market
- by Chon, Seung-Hyun Dec 2, 2021 05:54am
- The premium vaccine market that consists of vaccines used to prevent diseases like shingles, pneumococcal vaccines, etc has contracted greatly. Analysts believe that the demand for other vaccines had decreased due to medical institutions prioritizing COVID-19 vaccinations. However, the cervical cancer vaccine market continued to show growth due
- Policy
- MFDS reviews Pfizer COVID-19 vaccine used without dilution
- by Lee, Tak-Sun Dec 2, 2021 05:54am
- On the 30th, the Ministry of Food and Drug Safety had announced that it had started reviewing the approval of Pfizer’s COVID-19 vaccine that does not require dilution &8211; ‘Comirnaty inj. 0.1㎎/㎖ (registered name)’ &8211; after the company applied for the authorization of its import product license. The product contains the same a
- Policy
- Did Mooncare truly reinforce coverage for rare diseases?
- by Eo, Yun-Ho Dec 1, 2021 05:57am
- The voice requesting expanded coverage for patients with rare diseases had been exceptionally high this year in the 4th year of Mooncare. Starting with NA discussions held to enhance coverage of innovative new drugs for rare genetic disorders in May by the NA Health and Welfare Committee member Sunwoo Kang, NA members Byungwon Kang, Woni Kim,
- Company
- Prevenar 13 sales take ‘roller-coaster’ ride with COVID-19
- by Chon, Seung-Hyun Dec 1, 2021 05:56am
- Sales of the pneumococcal vaccine ‘Prevenar 13’ took a rollercoaster ride in one year, enjoying an upsurge for a short period of time then plummeting in just a single year. The vaccine enjoyed reflective benefits in the early phases of the COVID-19 pandemic but dropped sharply after COVID-19 vaccinations began in earnest. According to the p
